Showing results (111-120 of 421) with videos related to
Sort By:
Pageof 43
Cancer Prevention Research (Philadelphia, Pa.)|January 14, 2009
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman, Catherine M Tangen, Phyllis J Goodman, et al.Hematology/Oncology Clinics of North America|July 25, 2006
Chemoprevention of prostate cancerTimothy C Brand, Edith D Canby-Hagino, A Pratap Kumar, et al.The Journal of Urology|May 16, 2006
The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman, Ian M Thompson, Catherine M Tangen, et al.Clinical Prostate Cancer|March 30, 2004
Ten-year survival in patients with metastatic prostate cancerCatherine M Tangen, James R Faulkner, E David Crawford, et al.Urologia Internationalis|May 26, 2012
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation studyYuanyuan Liang, Norma S Ketchum, Christopher Louden, et al.Cancer|May 31, 2013
The Prostate Cancer Prevention Trial risk calculator and the relationship between prostate-specific antigen and biopsy outcomeAndrew J Vickers, Daniel D Sjoberg, Donna P Ankerst, et al.Current Urology Reports|May 5, 2005
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?Edith D Canby-Hagino, Gregory P Swanson, E David Crawford, et al.JAMA|January 18, 2006
Erectile dysfunction and subsequent cardiovascular diseaseIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.World Journal of Urology|November 23, 2017
Men with family history of prostate cancer have a higher risk of disease recurrence after radical prostatectomyMark Thalgott, Martina Kron, Johannes M Brath, et al.Neoplasia (New York, N.Y.)|November 22, 2007
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutineRita Ghosh, Gretchen E Garcia, Katherine Crosby, et al.Pageof 43